The effect of assessing genetic risk of prostate cancer on the use of PSA tests in primary care - Forskning

DOI

https://doi.org/10.1371/journal.pmed.1003033
Forlagets udgivne version

Background Assessing genetic lifetime risk for prostate cancer has been proposed as a means of risk stratification to identify those for whom prostate-specific antigen (PSA) testing is likely to be most valuable. This project aimed to test the effect of introducing a genetic test for lifetime risk of prostate cancer in general practice on future PSA testing. Methods and findings We performed a cluster randomized controlled trial with randomization at the level of general practices (73 in each of two arms) in the Central Region (Region Midtjylland) of Denmark. In intervention practices, men were offered a genetic test (based on genotyping of 33 risk-associated single nucleotide polymorphisms) in addition to the standard PSA test that informed them about lifetime genetic risk of prostate cancer and distinguished between “normal” and “high” risk. The primary outcome was the proportion of men having a repeated PSA test within 2 years. A multilevel logistic regression model was used to test the association. After applying the exclusion criteria, 3,558 men were recruited in intervention practices, with 1,235 (34.7%) receiving the genetic test, and 4,242 men were recruited in control practices. Men with high genetic risk had a higher propensity for repeated PSA testing within 2 years than men with normal genetic risk (odds ratio [OR] = 8.94, p < 0.01). The study was conducted in routine practice and had some selection bias, which is evidenced by the relatively large proportion of younger and higher income participants taking the genetic test. Conclusions Providing general practitioners (GPs) with access to a genetic test to assess lifetime risk of prostate cancer did not reduce the overall number of future PSA tests. However, among men who had a genetic test, knowledge of genetic risk significantly influenced future PSA testing.

Originalsprog	Engelsk
Artikelnummer	e1003033
Tidsskrift	PLOS Medicine
Vol/bind	17
Nummer	2
Sider (fra-til)	e1003033
Antal sider	14
ISSN	1549-1277
DOI	https://doi.org/10.1371/journal.pmed.1003033
Status	Udgivet - 2020

Find uddannelse

Studievejledning

Besøg AU

Kvalitet

Find

Aktuel forskning

Talent

Virksomheder

Kommuner og regioner

Gymnasier

Myndigheder

Organisation

Kontakt

Profil

Job

Om AU

The effect of assessing genetic risk of prostate cancer on the use of PSA tests in primary care: A cluster randomized controlled trial

DOI